Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BBA Relief Act Seeks By-Category Device Grouping Under Outpatient PPS

This article was originally published in The Gray Sheet

Executive Summary

A two-to-three year transitional payment period for pass-through devices in a category-based system under the Health Care Financing Administration's hospital outpatient prospective payment system would begin once the first device from an individual category receives payment.

You may also be interested in...



Legislators Finalize BBA Relief Measure; White House Threatens Veto

Two provisions of Reps. Jim Ramstad (R-Minn) and Karen Thurman's (D-Fla.) Medicare Patient Access to Technology Act (HR 4395) apparently did not survive eleventh-hour maneuvering between the White House and House Republicans in negotiating this year's Balanced Budget Act relief package.

Legislators Finalize BBA Relief Measure; White House Threatens Veto

Two provisions of Reps. Jim Ramstad (R-Minn) and Karen Thurman's (D-Fla.) Medicare Patient Access to Technology Act (HR 4395) apparently did not survive eleventh-hour maneuvering between the White House and House Republicans in negotiating this year's Balanced Budget Act relief package.

Safety Needle Bill For Public/Private Hospitals Awaits Senate Approval

Public and private hospital employers would be required to implement the use of safety-designed needles and sharps under two pieces of bipartisan legislation currently working through Congress.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013945

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel